Patent ID: 6545028
Filing Date: 2003-04-08
Classification: A61K,A61P,G01N,Y02A

Abstract:
A method for treatment or alleviation of a disease, condition or disorder selected from the group consisting of inflammatory bowel disease, Chron's disease, colitis ulcerosa, Coeliac disease, dermatitis herpetiformis, dermatomyositis, enteritis allergia, erytherma nodosum leprosum, ileitis regionalis, psoriasis, purpura, scleritis or scleroderma, said method comprising administering to a living body in need thereof an effective amount at least one compound selected from the group consisting ofan imidazole derivative selected from the group consisting of 1-[(2-chlorophenyl)-diphenyl-methyl]-1H-imidazole (Clotrimazole); 1-[(3-chlorophenyl)-diphenyl-methyl]-1H-imidazole; 1-[(4-chlorophenyl)-diphenyl-methyl]-1H-imidazole; 1-[(2-chlorophenyl)-(4-hydroxyphenyl)-phenyl-methyl]-1H-imidazole; 1-[(3-chlorophenyl)-(4-hydroxyphenyl)-phenyl-methyl]-1H-imidazole; 1-[(4-chlorophenyl)-(4-hydroxyphenyl)-phenyl-methyl]-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]-1H-imidazole (Miconazole); 1-Acetyl-4[4-[(2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4yl]methoxy]phenyl]piperazine (Ketoconazole); 1-[2-[(4-chlorophenyl)methoxyl]-2-(2,4-dichlorophenyl)ethyl]-1H-imidacole (Econazole); 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenylthio)butyl]imidazole mononitrate (Butoconazole); 2â€²,4â€²-dichloro-2-imidazol-1-ylacetophenone-(Z)â€”Oâ€”(2,4-dichlorobenzyl)oxime mononitrate (Oxiconazole); 1-[2,4-dichloro-&bgr;-(4-chlorobenzyl)thiophenethyl]imidazole nitrate (Sulconazole); and 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole (Thioconazole); a triazole derivative selected from the group consisting of2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol (Fluconazole); 1-{4-[[2-(2,4-dichlorophenyl)r-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-c-4-yl]methoxy]-phenyl}-4-isopropylpiperazine (Terconazole); and (Â±)-2-sec-butyl-4-[4-(4-{4-[(2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl}-piperazin-1-yl)phenyl]-2,4-dihydro-1,2,4-triazol-3-one (Itraconazole); and a nitroimidazole derivative selected from the group consisting of2-methyl-5-nitroimidazole-1-ethanol (Metronidazole); 1-[2-(ethylsulphonyl)ethyl]-2-methyl-5-nitroimidazole (Tinidazole); 4-[2-(5-nitroimidazol-1-yl)ethyl]morpholine (Nimorazole); 1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol (Ornidazole); and N-benzyl-2-(2-nitroimidazol-1-yl)acetamide (Benznidazole).